You Have a p-tau217 Result. What Now?

You Have a p-tau217 Result. What Now?

Direct-to-consumer Alzheimer’s blood tests are now being sold by mail in our area, typically for a few hundred dollars, without a referral and without any evaluation of how you are actually functioning. You can get these tests directly from the labs in the area. You can get the order online along with other biomarkers. If you have a result in hand — or you are deciding whether to order one — this is what the number means, what it doesn’t, and what a sensible next step looks like. The same reasoning applies to the other Alzheimer’s blood biomarkers now being marketed directly to consumers.

What the test measures

p-tau217 is a protein fragment measurable in blood. Its level tracks with amyloid buildup in the brain, one of the two hallmark changes of Alzheimer’s disease. It is a genuine scientific advance. A decade ago, answering this question required a spinal tap or a PET scan costing thousands of dollars.

A high result means Alzheimer’s-type brain changes are more likely to be present than not. Think of it as a risk indication.

What it does not tell you

Whether you have dementia. Brain changes and disease are not the same thing. Roughly one in four people in their seventies with completely normal thinking have amyloid in their brains. Many will never develop symptoms in their lifetime.

When, or whether, symptoms would start. The test has no timeline in it. Two people with identical results can have very different futures.

Anything about your actual thinking. This is the important one. The test measures biology, not function. It cannot tell you whether your memory is where it should be for your age and education, whether the word-finding trouble you’ve noticed is meaningful, or whether anything has changed in the past two years.

A clean yes or no. Many results land in an indeterminate middle zone. Thresholds also differ between laboratories, so “positive” from one vendor is not identical to “positive” from another.

Whether something else explains it. Reduced kidney function raises p-tau217 independent of anything happening in the brain. So do several other conditions. Without a clinician reviewing your medical picture, a high number can be misread.

What you can’t tell from the inside

There is a second gap, and it is the one people are least prepared for: how you rate your own memory is not reliable information either — in both directions.

Worry about memory tracks mood, sleep, and temperament at least as closely as it tracks cognition. Some of the most worried people we evaluate are performing perfectly normally. What they are describing is stress, a medication, or a temperament that notices everything. Being worried is not evidence of a problem.

The reverse matters more. The ability to notice cognitive change tends to fade early, as part of the change itself. So the people with the most going on are frequently the ones reporting that nothing is wrong — and meaning it. A wife or a son usually sees it a year or two before the person does.

This is why “I feel fine” is not reassurance and “I’m worried” is not a diagnosis, and why neither one, on its own, tells you what to do with a test result.

The missing half

A biomarker tells you about risk. A cognitive baseline tells you about you.

Here is why that distinction matters more than most people expect. If you were told your cholesterol was elevated, the number would be useful — but no physician would act on it without knowing your blood pressure, your family history, and how you actually feel walking up a flight of stairs. The lab value is one input among several.

Cognition works the same way, with one added wrinkle: what matters most is not any single measurement but change over time. And you cannot measure change without a starting point. A cognitive baseline established while you are well is worth far more than the most sophisticated evaluation performed after you are already worried — because only the first one lets anyone tell the difference between normal aging, a bad testing day, and something real.

Most people get this backwards. They buy the biology and skip the function. The biology, on its own, generates anxiety without direction.

What to do next

Negative result, no symptoms. Reassuring with respect to Alzheimer’s specifically. It does not rule out other causes of cognitive change. A baseline is still the highest-value thing you can do, precisely because you are well right now.

Negative result, but you have noticed changes. Take this seriously rather than filing it away. Sleep apnea, thyroid dysfunction, medication effects, depression, alcohol, and vascular disease all affect thinking and all are more treatable than Alzheimer’s. A negative biomarker makes a workup more urgent, not less.

Positive result, no symptoms. You do not have Alzheimer’s disease. You have information about elevated risk. The useful responses are a cognitive baseline, honest attention to modifiable risk factors — blood pressure, hearing, sleep, exercise, alcohol — and unhurried planning done while you are at full capacity.

Positive result, and you or your family have noticed changes. This warrants a proper diagnostic evaluation with a clinician, not another test.

Indeterminate result. Common, and not a failure of the test. It needs clinical context to mean anything. As someone who has been trained in memory disorders.

Two practical cautions

Before you order. Results you obtain outside a clinical relationship still create a record. Long-term care and life insurance underwriting can ask about known test results; unlike genetic testing, blood biomarkers carry limited legal protection here. This is worth understanding before you test, not after. We are not attorneys and this is not legal advice, but it is a question worth asking yours.

Before you act. No one should restructure finances, change living arrangements, or make irreversible decisions on the basis of a single number delivered by mail with no one to interpret it. Whatever the result, it will still be true in six weeks.

What we do with a result like this

Treasure Coast Cognition is a direct-pay neuropsychology practice built around proactive, lifelong cognitive care. If you bring us a biomarker result, we:

review it against your full medical picture, including the conditions that can distort it

establish a formal cognitive baseline using measures sensitive enough to detect real change later

tell you plainly what the result does and does not imply for you specifically through partnership with your medical team

build a monitoring schedule so that future testing measures change rather than starting over

coordinate with your physician or a neurologist when a diagnostic workup is warranted

Sometimes our answer is that no further evaluation is needed and you should get on with your life.

You can read more here from the Alzheimer’s Association: https://www.alz.org/news/2026/fda-clearance-elecsys-ptau217-blood-test-alzheimers

One more thing worth knowing: p-tau217 tracks amyloid, one of Alzheimer's two hallmark brain changes. The other is tau, in the form of tangles — and tangle burden tracks much more closely with actual symptoms than amyloid does. Researchers are now testing a blood marker for tangle burden directly (called MTBR-tau243) that may predict cognitive decline more precisely than amyloid markers alone. Promising, and not yet available outside research studies: https://www.alzforum.org/news/conference-coverage/adding-emtbr-tau243-p-tau217-sharpens-ad-diagnosis

The one thing to take away

The blood test tells you something about your brain’s biology. It tells you nothing about your thinking. Get the baseline if you want the blood test — that is the half that makes the number useful.

Questions about a result you’ve received? We’re happy to talk it through.

(772) 202-0486 · luke@treasurecoastcognition.com